Taken together, our study implies that PRMT1/PRMT5 are important mediators of EWS-FLI1 oncogenicity and that drug targeting of PRMT1/PRMT5 in combination with DNA damaging chemotherapies could be an effective therapeutic strategy for the treatment of ES patients. This evidence concerns the gene PRMT5 and Ewing sarcoma.